Tumor Registry of Advanced Renal Cell Carcinoma

Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00610012

Acronym

RCC-Registry

Enrollment

1500

Registered

2008-02-07

Start date

2007-12-31

Completion date

2020-05-15

Last updated

2020-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Advanced Renal Cell Carcinoma, MRCC, Therapy-reality, Observation, Registry, RCC, ARCC, Germany, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Cancer, Sorafenib, Sunitinib, Interferon, Interleukin, Temsirolimus, Pazopanib, Cytokines, VEGF

Brief summary

The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.

Detailed description

The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy * Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Documentation of therapies	9 years, 3 years per patient

Secondary

Measure	Time frame
Documentation of response rate and adverse reactions; development of a numeric prognostic score	9 years

Countries

Germany

Outcome results